II期临床-话题@MedSci

#II期临床#

478篇内容 | 2557人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524607, encodeId=785d152460ec6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, objectType=article, longId=77492, objectId=45e5e749218, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45e5e749218, replyNumber=0, likeNumber=25, createdTime=2016-09-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45e5e749218, moduleTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45e5e749218)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524605, encodeId=27bf152460552, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, objectType=article, longId=77042, objectId=be26e7042b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be26e7042b9, replyNumber=0, likeNumber=24, createdTime=2016-09-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be26e7042b9, moduleTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be26e7042b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524606, encodeId=35cc15246062c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功, objectType=article, longId=77044, objectId=8f4ee7044a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f4ee7044a1, replyNumber=0, likeNumber=64, createdTime=2016-09-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f4ee7044a1, moduleTitle=喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f4ee7044a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524604, encodeId=633e152460459, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功, objectType=article, longId=75977, objectId=1959e5977e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1959e5977e7, replyNumber=0, likeNumber=69, createdTime=2016-08-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1959e5977e7, moduleTitle=诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1959e5977e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524603, encodeId=7f7a152460330, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Radius新型骨质疏松症药物abaloparatide III期临床获得成功，将成礼来重磅药物Forteo（特立帕肽）劲敌, objectType=article, longId=75431, objectId=5c87e54317c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c87e54317c, replyNumber=0, likeNumber=45, createdTime=2016-08-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c87e54317c, moduleTitle=Radius新型骨质疏松症药物abaloparatide III期临床获得成功，将成礼来重磅药物Forteo（特立帕肽）劲敌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c87e54317c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524602, encodeId=4eed152460201, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据, objectType=article, longId=74630, objectId=4456e46306b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4456e46306b, replyNumber=0, likeNumber=87, createdTime=2016-08-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4456e46306b, moduleTitle=卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4456e46306b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524601, encodeId=0bd71524601a4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点, objectType=article, longId=73929, objectId=f3abe392977, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3abe392977, replyNumber=0, likeNumber=55, createdTime=2016-07-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3abe392977, moduleTitle=阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3abe392977)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524600, encodeId=4a44152460032, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, objectType=article, longId=73839, objectId=0b9ee38391d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9ee38391d, replyNumber=0, likeNumber=53, createdTime=2016-07-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9ee38391d, moduleTitle=又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9ee38391d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524599, encodeId=9277152459973, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Sutent（舒坦）辅助治疗肾细胞癌III期临床获得成功（S-TRAC研究）, objectType=article, longId=72833, objectId=6650e283369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6650e283369, replyNumber=0, likeNumber=0, createdTime=2016-07-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6650e283369, moduleTitle=Sutent（舒坦）辅助治疗肾细胞癌III期临床获得成功（S-TRAC研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6650e283369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524597, encodeId=1774152459e1c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, objectType=article, longId=71847, objectId=9b2ae184708, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b2ae184708, replyNumber=0, likeNumber=55, createdTime=2016-07-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b2ae184708, moduleTitle=肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b2ae184708)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524598, encodeId=1f44152459833, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功, objectType=article, longId=71850, objectId=e5a0e1850d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a0e1850d9, replyNumber=0, likeNumber=55, createdTime=2016-07-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a0e1850d9, moduleTitle=辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5a0e1850d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524596, encodeId=f22b15245967f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=武田全球诺罗病毒（norovirus）疫苗TAK-214进入II期临床开发, objectType=article, longId=71371, objectId=00a9e137141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a9e137141, replyNumber=0, likeNumber=61, createdTime=2016-06-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a9e137141, moduleTitle=武田全球诺罗病毒（norovirus）疫苗TAK-214进入II期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a9e137141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524594, encodeId=d0f8152459439, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ADA 2016：默沙东生物类似物MK-1293治疗1型和2型糖尿病III期临床疗效媲美来得时（Lantus）, objectType=article, longId=71288, objectId=4a51e128881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a51e128881, replyNumber=0, likeNumber=138, createdTime=2016-06-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a51e128881, moduleTitle=ADA 2016：默沙东生物类似物MK-1293治疗1型和2型糖尿病III期临床疗效媲美来得时（Lantus）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a51e128881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524595, encodeId=09ae152459567, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, objectType=article, longId=71290, objectId=e56ee129027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56ee129027, replyNumber=0, likeNumber=79, createdTime=2016-06-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56ee129027, moduleTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56ee129027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524593, encodeId=2490152459342, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ADA 2016：诺和诺德第二款兼具降糖及减肥的降糖药semaglutide（索马鲁肽）III期临床疗效显著, objectType=article, longId=71033, objectId=e336e1033ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e336e1033ae, replyNumber=0, likeNumber=0, createdTime=2016-06-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e336e1033ae, moduleTitle=ADA 2016：诺和诺德第二款兼具降糖及减肥的降糖药semaglutide（索马鲁肽）III期临床疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e336e1033ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524592, encodeId=6aca15245925d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, objectType=article, longId=70647, objectId=2a45e0647b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a45e0647b2, replyNumber=0, likeNumber=76, createdTime=2016-06-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a45e0647b2, moduleTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a45e0647b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524591, encodeId=04af152459166, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=IL-6单抗sirukumab对类风湿性关节炎 III期临床结果喜人（SIRROUND-D试验）, objectType=article, longId=70473, objectId=9133e047362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9133e047362, replyNumber=0, likeNumber=64, createdTime=2016-06-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9133e047362, moduleTitle=IL-6单抗sirukumab对类风湿性关节炎 III期临床结果喜人（SIRROUND-D试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9133e047362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524590, encodeId=9756152459060, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, objectType=article, longId=70373, objectId=0c80e0373e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c80e0373e2, replyNumber=0, likeNumber=0, createdTime=2016-06-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c80e0373e2, moduleTitle=ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c80e0373e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524589, encodeId=e2cf15245893d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请, objectType=article, longId=68953, objectId=268b6895329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=268b6895329, replyNumber=0, likeNumber=51, createdTime=2016-05-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=268b6895329, moduleTitle=重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=268b6895329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524588, encodeId=d51c1524588ef, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=醋酸乌利司他治疗子宫肌瘤，III期临床获得成功, objectType=article, longId=67902, objectId=2f076e90229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f076e90229, replyNumber=0, likeNumber=70, createdTime=2016-05-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f076e90229, moduleTitle=醋酸乌利司他治疗子宫肌瘤，III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f076e90229)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据

2016-09-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler

2016-09-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

喜讯！阿斯利康哮喘药物benralizumab两项III期临床取得成功

2016-09-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华新一代免疫调节剂BAF312（siponimod）治疗继发进展型多发性硬化症（SPMS）III期临床获得成功

2016-08-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Radius新型骨质疏松症药物abaloparatide III期临床获得成功，将成礼来重磅药物Forteo（特立帕肽）劲敌

2016-08-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

卫材公布新型抗癌药Halaven治疗软组织肉瘤III期临床新数据

2016-08-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康复方抗生素Zavicefta达医院获得性肺炎III期临床主要终点

2016-07-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

又一个仿制药！安进/艾尔建公布赫赛汀仿制药III期临床积极数据

2016-07-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Sutent（舒坦）辅助治疗肾细胞癌III期临床获得成功（S-TRAC研究）

2016-07-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

肝癌患者福音！拜耳抗癌药Stivarga治疗肝细胞癌III期临床获得成功

2016-07-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞PCSK9抑制剂类降脂药bococizumab 4个降脂III期临床获得成功

2016-07-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

武田全球诺罗病毒（norovirus）疫苗TAK-214进入II期临床开发

2016-06-23

智智灵药 (审核中...)

前往app查看评论内容

#II期临床#

ADA 2016：默沙东生物类似物MK-1293治疗1型和2型糖尿病III期临床疗效媲美来得时（Lantus）

2016-06-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点

2016-06-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ADA 2016：诺和诺德第二款兼具降糖及减肥的降糖药semaglutide（索马鲁肽）III期临床疗效显著

2016-06-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期

2016-06-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

IL-6单抗sirukumab对类风湿性关节炎 III期临床结果喜人（SIRROUND-D试验）

2016-06-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ASCO 2016：CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果（MONARCH 1试验）

2016-06-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

重磅！卫材新型抗癌药Halaven中国乳腺癌III期临床获得成功，上半年向CFDA提交新药申请

2016-05-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

醋酸乌利司他治疗子宫肌瘤，III期临床获得成功

2016-05-12

科室
- - 订阅+
  - 更多科室
工具
服务